Drug controller’s nod for Omicron-specific mRNA-based vaccine
PTI, Jun 21, 2023, 10:14 AM IST
India’s drug controller has granted emergency use authorisation for the Omicron-specific mRNA-based booster vaccine developed by Gennova Biopharmaceuticals under Mission Covid Suraksha, the Department of Biotechnology said on Tuesday.
The Department of Biotechnology (DBT) had facilitated establishing Gennova’s mRNA-based next-generation vaccine manufacturing for developing the platform technology from proof of concept till Phase I clinical trial of the prototype vaccine developed against the Wuhan strain, an official statement said.
”GEMCOVAC-OM is an Omicron-specific mRNA-based booster vaccine developed using the indigenous platform technology by Gennova in collaboration with DBT,” it said.
”GEMCOVAC-OM getting Emergency Use Authorisation from the office of the Drug Controller General of India is a testimony of our efforts to initiate, nurture and enable this ‘pandemic ready’ technology,” Sanjay Singh, CEO of Gennova Biopharmaceuticals Ltd, said.
GEMCOVAC-OM is a thermostable vaccine which does not require ultra-cold chain infrastructure, making it easy for pan-India deployment.
”Infrastructure to deploy vaccines in India at 2-8 degrees Celsius exists today and this innovation is tailored for the existing established supply-chain infrastructure. The vaccine does not need ultra-low temperature conditions for transport and storage,” Science and Technology Minister Jitendra Singh said.
The vaccine is delivered intradermally using a needle-free injection device system.
The project was supported under ‘Mission Covid Suraksha’, the Indian Covid-19 Vaccine Development Mission’ by DBT’s dedicated Mission Implementation Unit at Biotechnology Industry Research Assistance Council (BIRAC), for further clinical development and scale up of the prototype vaccine, which received emergency use authorisation in June last year.
Rajesh S Gokhale, Secretary, DBT, and Chairperson, BIRAC, said GEMCOVAC-OM was developed using the mRNA-based disease agnostic platform technology which can be used to make other vaccines in a relatively short development timeline.
India has now developed two mRNA vaccines against COVID-19 using this rapid-disease-agnostic platform technology.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Nearsightedness is at epidemic levels – and the problem begins in childhood
Study finds genetic basis for link between depression, heart disease
World Malaria Day: WHO calls for equitable health access
What role does genetics play in breast cancer? How can genetic testing help with early breast cancer diagnosis?
Father’s diet can affect anxiety in sons, metabolism in daughters: Study in mice finds
MUST WATCH
Latest Additions
Wait for few more days: Kharge on Cong candidates for Amethi, Rae Bareli
Wait for few more days: Kharge on Cong candidates for Amethi, Rae Bareli
Bus catches fire after tyre burst on Mumbai-Pune Expressway; all passengers safe
Chhattisgarh: CBI takes over probe in Bhuneshwar Sahu murder case
Make Modi PM for third time to end terrorism and Naxalism: Shah